Evidence map›Paper›PMID 26716456›Full record

ArticlePloS one2015

Isoalantolactone Enhances the Radiosensitivity of UMSCC-10A Cells via Specific Inhibition of Erk1/2 Phosphorylation.

Yonggang Fan, Zhiyong Weng, Hongguo Gao, Jiehua Hu, Hongyan Wang, Lihua Li, Hua Liu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Molecules (Basel, Switzerland) · 2021
    Review
  7. 11, 13-Dehydro Lactone Moiety in Gynecologic Cancer Cells.Iranian journal of public health · 2020
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Yonggang FanDepartment of Cell Biology, Liaoning Medical University, Jinzhou, Liaoning, China.
Zhiyong WengDepartment of Cell Biology, Liaoning Medical University, Jinzhou, Liaoning, China.
Hongguo GaoDepartment of clinical laboratory, Daqing oilfield general hospital, Daqing, Heilongjiang, China.
Jiehua HuInformation Center, Logistics college, Naval University of Engineering, Tanggu, Tianjin, China.
Hongyan WangDepartment of clinical laboratory, Daqing oilfield general hospital, Daqing, Heilongjiang, China.
Lihua LiDepartment of Cell Biology, Liaoning Medical University, Jinzhou, Liaoning, China.
Hua LiuDepartment of Cell Biology, Liaoning Medical University, Jinzhou, Liaoning, China.
Jinzhou Medical University · CNDaqing Oilfield General Hospital · CNNaval University of Engineering · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough radiotherapy is one of the mainstream approaches for the treatment of head and neck squamous cell carcinoma (HNSCC), this cancer is always associated with resistance to radiation. In this study, the mechanism of action of isoalantolactone as well as its radiosensitizing effect was investigated in UMSCC-10A cells.

methodsThe radiosensitization of UMSCC-10A cells treated with isoalantolactone was analyzed by colony formation assay. The radiosensitization effects of isoalantolactone on cell proliferation, cell cycle and apoptosis regulation were examined by BrdU incorporation assay, DNA content assay and flow cytometry, respectively. Western blotting was performed to determine the effects of isoalantolactone combined with radiation on the protein expression of Mek, extracellular signal-regulated kinase (Erk1/2) as well as phosphorylated Mek and Erk1/2. Erk1/2 knockdown by siRNA was used to confirm that isoalantolactone specifically inhibited the activation of Erk1/2 signaling pathway in UMSCC-10A cells.

resultsIsoalantolactone enhanced the radiosensitivity of UMSCC-10A cells; the sensitivity enhanced ratios (SERs) were 1.44 and 1.63, respectively, for 2.5 and 5 μM. Moreover, isoalantolactone enhanced radiation-induced cell proliferation and apoptosis and cell cycle arrested at G2/M phase. Furthermore, no marked changes were observed in the expression of total Erk1/2 and Mek protein after radiation treatment. However, isoalantolactone was significantly reduced radiation-induced the phosphorylation of Erk1/2, whereas it altered the phosphorylation of Mek to a lesser extent. In addition, the radiosensitivity of UMSCC-10A cells with Erk1/2 knockdown was increased. Isoalantolactone cannot further prevent the proliferation of UMSCC-10A cells with Erk1/2 knockdown which other mechanism regulated cell proliferation.

conclusionOur results suggested that isoalantolactone enhanced radiation-induced apoptosis, cell cycle arrested and reduced the cell proliferation of UMSCC-10A cells via specifically inhibited the phosphorylation of Erk1/2. Thus a low concentration of isoalantolactone may be used to overcome the resistance of UMSCC-10A cells to radiation and may be a promising radiosensitizer in cancer therapy.

Indexed as

AnimalsApoptosisApoptosis Regulatory ProteinsCarcinoma, Squamous CellCell DivisionCell Line, TumorCell ProliferationExtracellular Signal-Regulated MAP KinasesG2 PhaseHead and Neck NeoplasmsHep G2 CellsHumansMAP Kinase Signaling SystemPhosphorylationRadiation-Sensitizing AgentsRadiation ToleranceApoptosis Regulatory ProteinsExtracellular Signal-Regulated MAP KinasesisoalantolactoneRadiation-Sensitizing AgentsSesquiterpenes

Identifiers

PMID26716456
PMCPMC4696678
OpenAlexW2213851841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.